









Markets
/
Stocks
/
nasdaq-rna
/

Avidity Biosciences Inc

RNA

69.780USD

-0.020-0.03%

Close 11/06, 16:00（ET）Quotes delayed by 15 min

8.43BMarket Cap

LossP/E TTM



Avidity Biosciences Inc

69.780

-0.020-0.03%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Avidity Biosciences Inc

Currency: USD Updated: 2025-11-06

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Avidity Biosciences Inc's Score

Industry at a Glance

Industry Ranking

46 / 159

Overall Ranking

135 / 4615

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 15 analysts

Hold

Current Rating

71.933

Target Price

+3.06%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Avidity Biosciences Inc Highlights

StrengthsRisks

Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 18.14% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 10.90M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 10.90M.

Undervalued

The company’s latest PE is -19.60, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 143.66M shares, decreasing 1.44% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 1.51K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.87.

Financial Health

Currency: USD Updated: 2025-11-06

The company's current financial score is 6.55, which is lower than the Pharmaceuticals industry's average of 7.76. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 3.85M, representing a year-over-year increase of 88.12%, while its net profit experienced a year-over-year increase of 122.22%.

Score

Industry at a Glance

Previous score

6.55

Change



Financials

7.51

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.11

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.60

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.35

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.16

Key Metrics

Free cash flow

No Data

Avidity Biosciences Inc's Company Valuation

Currency: USD Updated: 2025-11-06

The company’s current valuation score is 6.74, which is lower than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is -19.60, which is -91.70% below the recent high of -1.63 and -0.32% above the recent low of -19.66.

Score

Industry at a Glance

Previous score

6.74

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 46/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-06

The company’s current earnings forecast score is 6.93, which is lower than the Pharmaceuticals industry's average of 7.77. The average price target for Avidity Biosciences Inc is 72.00, with a high of 96.00 and a low of 65.00.

Score

Industry at a Glance

Previous score

6.93

Change

Support & Resistance

No Data

Analyst Rating

Based on 15 analysts

Hold

Current Rating

71.933

Target Price

+3.06%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Avidity Biosciences Inc

RNA

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-06

The company’s current price momentum score is 9.76, which is higher than the Pharmaceuticals industry's average of 6.90. Sideways: Currently, the stock price is trading between the resistance level at 78.16 and the support level at 53.75, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.76

Change

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(1)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

2.270

Buy

RSI(14)

79.390

Buy

STOCH(KDJ)(9,3,3)

62.223

Sell

ATR(14)

2.427

High Vlolatility

CCI(14)

51.627

Neutral

Williams %R

3.014

Overbought

TRIX(12,20)

2.002

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

69.812

Sell

MA10

67.748

Buy

MA20

58.247

Buy

MA50

50.188

Buy

MA100

43.427

Buy

MA200

37.052

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-06

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 5.76. The latest institutional shareholding proportion is 99.26%, representing a quarter-over-quarter decrease of 15.44%. The largest institutional shareholder is The Vanguard, holding a total of 13.22M shares, representing 9.00% of shares outstanding, with 14.07% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

15.82M

+3.44%

The Vanguard Group, Inc.

Star Investors

9.23M

+0.06%

Janus Henderson Investors

12.13M

+12.57%

T. Rowe Price Associates, Inc.

Star Investors

10.67M

-4.79%

Wellington Management Company, LLP

9.25M

-4.49%

BlackRock Institutional Trust Company, N.A.

8.18M

-2.54%

RA Capital Management, LP

7.27M

+15.33%

Avoro Capital Advisors LLC

7.05M

-7.54%

Bristol Myers Squibb

5.08M

RTW Investments L.P.

9.62M

+9.97%

Risk Assessment

Currency: USD Updated: 2025-11-06

The company’s current risk assessment score is 4.59, which is lower than the Pharmaceuticals industry's average of 5.15. The company's beta value is 0.91. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.